QQQ   269.77 (+1.50%)
AAPL   437.55 (+2.94%)
MSFT   216.88 (+5.79%)
FB   253.05 (-0.24%)
GOOGL   1,486.31 (-0.11%)
AMZN   3,119.73 (-1.42%)
NVDA   439.52 (+3.52%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,479.84 (+3.43%)
MU   50.34 (+0.56%)
GE   6.12 (+0.66%)
AMD   77.46 (+0.04%)
T   29.62 (+0.14%)
F   6.70 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.93 (+3.45%)
NFLX   499.12 (+2.09%)
DIS   116.39 (-0.47%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
QQQ   269.77 (+1.50%)
AAPL   437.55 (+2.94%)
MSFT   216.88 (+5.79%)
FB   253.05 (-0.24%)
GOOGL   1,486.31 (-0.11%)
AMZN   3,119.73 (-1.42%)
NVDA   439.52 (+3.52%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,479.84 (+3.43%)
MU   50.34 (+0.56%)
GE   6.12 (+0.66%)
AMD   77.46 (+0.04%)
T   29.62 (+0.14%)
F   6.70 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.93 (+3.45%)
NFLX   499.12 (+2.09%)
DIS   116.39 (-0.47%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
QQQ   269.77 (+1.50%)
AAPL   437.55 (+2.94%)
MSFT   216.88 (+5.79%)
FB   253.05 (-0.24%)
GOOGL   1,486.31 (-0.11%)
AMZN   3,119.73 (-1.42%)
NVDA   439.52 (+3.52%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,479.84 (+3.43%)
MU   50.34 (+0.56%)
GE   6.12 (+0.66%)
AMD   77.46 (+0.04%)
T   29.62 (+0.14%)
F   6.70 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.93 (+3.45%)
NFLX   499.12 (+2.09%)
DIS   116.39 (-0.47%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
QQQ   269.77 (+1.50%)
AAPL   437.55 (+2.94%)
MSFT   216.88 (+5.79%)
FB   253.05 (-0.24%)
GOOGL   1,486.31 (-0.11%)
AMZN   3,119.73 (-1.42%)
NVDA   439.52 (+3.52%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,479.84 (+3.43%)
MU   50.34 (+0.56%)
GE   6.12 (+0.66%)
AMD   77.46 (+0.04%)
T   29.62 (+0.14%)
F   6.70 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.93 (+3.45%)
NFLX   499.12 (+2.09%)
DIS   116.39 (-0.47%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
Log in

NASDAQ:TNDMTandem Diabetes Care Price Target & Analyst Ratings

$105.41
+0.95 (+0.91 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$101.26
Now: $105.41
$106.70
50-Day Range
$79.48
MA: $94.92
$104.28
52-Week Range
$43.69
Now: $105.41
$110.80
Volume1.30 million shs
Average Volume848,404 shs
Market Capitalization$6.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.56

Analyst Ratings

Tandem Diabetes Care (NASDAQ:TNDM) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Tandem Diabetes Care in the last 12 months. Their average twelve-month price target is $111.62, suggesting that the stock has a possible upside of 5.89%. The high price target for TNDM is $140.00 and the low price target for TNDM is $75.00. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.502.542.77
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $111.62$93.31$84.42$77.62
Price Target Upside: 5.89% upside6.26% upside8.74% upside4.45% upside

Tandem Diabetes Care (NASDAQ:TNDM) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Tandem Diabetes Care (NASDAQ:TNDM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/31/2020Raymond JamesBoost Price TargetOutperform$95.00 ➝ $116.00Low
7/31/2020Craig HallumBoost Price TargetBuy$102.00 ➝ $140.00High
7/31/2020Lake Street CapitalBoost Price TargetPositive ➝ Buy$125.00 ➝ $137.00High
7/31/2020SVB LeerinkBoost Price TargetMarket Perform$105.00 ➝ $115.00High
7/31/2020GuggenheimUpgradeNeutral ➝ Buy$130.00High
7/31/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $125.00High
7/7/2020CowenBoost Price TargetPositive ➝ Outperform$85.00 ➝ $110.00Low
7/6/2020CitigroupUpgradeNeutral ➝ Buy$94.00 ➝ $120.00Low
6/30/2020OppenheimerInitiated CoverageBuy$102.00Low
6/30/2020Bank of AmericaReiterated RatingHold$100.00Low
6/22/2020UBS GroupBoost Price TargetBuy$98.00 ➝ $106.00Low
5/1/2020Stifel NicolausBoost Price TargetHold$65.00 ➝ $75.00Medium
2/4/2020Robert W. BairdDowngradeOutperform ➝ Neutral$71.00 ➝ $75.00Low
3/8/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$77.00High
2/27/2019Piper Jaffray CompaniesUpgradeOverweight$67.00High
9/26/2018Dougherty & CoBoost Price TargetBuy$45.00 ➝ $56.00Low
8/30/2018Berenberg BankInitiated CoverageBuy ➝ Buy$50.00High
10/10/2017WedbushReiterated RatingOutperform$50.00 ➝ $17.00N/A
(Data available from 8/3/2018 forward)
This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.